If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Selegiline was approved for Parkinson's disease by the FDA in 1989. It had been known since the mid-1960s that high doses of deprenyl had psychostimulant effects. Selegiline was first shown to metabolize into levomethamphetamine and levoamphetamine in humans in 1978. The involvement of these metabolites in the effects and side effects of selegiline has remained controversial and unresolved in the decades afterwards. In any case, concerns about these metabolites have contributed to the development of newer MAO-B inhibitors like rasagiline and safinamide that lack such metabolites. The catecholaminergic activity enhancer (CAE) effects of selegiline became well-characterized and distinctly named in 1994. These effects had been observed much earlier, dating back to the 1960s and 1970s, but were not properly distinguished from the other actions of selegiline, like MAO-B inhibition, until the 1990s. More potent, selective, and/or expansive monoaminergic activity enhancers (MAEs), like phenylpropylaminopentane (PPAP) and benzofuranylpropylaminopentane (BPAP), were derived from selegiline and other compounds and were first described in 1988 and 1999, respectively. These drugs had been proposed for potential treatment of psychiatric disorders like depression as well as for Parkinson's disease and Alzheimer's disease, but were never developed or marketed. In the 1990s, J.
Promising results of health and medical research are reported: mouse-tested novel antibiotics class (including Zosurabalpin) against A. baumannii (3 Jan), small-trialed focused ultrasound for blood–brain barrier opening for better medication (Aducanumab) entry against Alzheimer's disease (3 Jan), a review supports the efficacy of exercise against depression (15 Jan), an available blood test to detect Alzheimer's disease with high accuracy using p-tau217 (22 Jan), one of two small-trialed gene therapies against DFNB9-deafness (24 Jan), phase 3-trialed dengue vaccine effective against at least two of four dengue types (31 Jan) Hazard research is published: ~240.000 particles of microplastic and nanoplastics (~90%) per liter are found in samples of plastic-bottled water (8 Jan), a study estimates harmful chemicals used in plastic materials have caused $249 billion U.S. healthcare system costs in 2018 (11 Jan), a study indicates fungal infections may be causing millions more deaths annually than thought (12 Jan), a study of European plastic waste exports to Vietnam finds a large fraction is dumped in nature and suggests air pollution from melting plastics and untreated wastewater have significant impact on health (18 Jan).
These species feature elements from groups I, II, III, IV, V, VI, VII, 0 (excluding hydrogen) of the periodic table. Due to their often similar reactivity, the elements in group 3 (Sc, Y, and La) and group 12 (Zn, Cd, and Hg) are also generally included, and the lanthanides and actinides are sometimes included as well. Main group compounds have been known since the beginnings of chemistry, e.g., elemental sulfur and the distillable white phosphorus. Experiments on oxygen, O2, by Lavoisier and Priestley not only identified an important diatomic gas, but opened the way for describing compounds and reactions according to stoichiometric ratios. The discovery of a practical synthesis of ammonia using iron catalysts by Carl Bosch and Fritz Haber in the early 1900s deeply impacted mankind, demonstrating the significance of inorganic chemical synthesis. Typical main group compounds are SiO2, SnCl4, and N2O. Many main group compounds can also be classed as "organometallic", as they contain organic groups, e.g., B(CH3)3. Main group compounds also occur in nature, e.g., phosphate in DNA, and therefore may be classed as bioinorganic. Conversely, organic compounds lacking (many) hydrogen ligands can be classed as "inorganic", such as the fullerenes, buckytubes and binary carbon oxides.
Sources: en.wikipedia.org
== Research == Other therapies are under investigation, including gene therapy. BioMarin is conducting clinical trials to investigate PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or 'PAL'), which is an enzyme substitution therapy in which the missing PAH enzyme is replaced with an analogous enzyme that also breaks down Phe (to ammonia and trans-cinnamic acid). PEG-PAL was in Phase 2 clinical development as of 2015, but was put on clinical hold in September 2021. In February 2022, the FDA issued a statement requiring further data from non-clinical studies to assess oncogenic risk resulting from PEG-PAL treatments.
== Early life and education == Shiva Ayyadurai was born Vellayappa Ayyadurai Shiva in 1963, in Bombay (now Mumbai), India. He grew up in the Muhavur village in Rajapalayam, Tamil Nadu. At the age of seven, he left with his family to live in the United States. He was raised in Livingston, New Jersey. In 1978, as a 14-year-old high school student, Ayyadurai attended a summer program at the Courant Institute of Mathematical Sciences of New York University (NYU) to study computer programming. While a student at Livingston High School in New Jersey, Ayyadurai volunteered at the University of Medicine and Dentistry of New Jersey (UMDNJ) where his mother worked. While there Leslie Michelson asked him to set up an electronic messaging system for 100 users at the medical school. In 1982, he registered the copyright for the source code and user documentation of the FORTRAN program called EMAIL. Ayyadurai's undergraduate degree from MIT was in electrical engineering and computer science; he took a master's degree in visual studies from the MIT Media Laboratory on scientific visualization; concurrently, he completed another master's degree in mechanical engineering, also from MIT; and in 2007, he obtained a PhD in biological engineering from MIT in systems biology, with his thesis focusing on modeling the whole cell by integrating molecular pathway models. In 2007, he was awarded a Fulbright U.S. Student Program grant to study the integration of Siddha, a system of traditional medicine developed in South India, with modern systems biology.
== Media impact == Real-life crime scene investigators and forensic scientists warn that popular television shows do not give a realistic picture of the work, often wildly distorting its nature, and exaggerating the ease, speed, effectiveness, drama, glamour, influence and comfort level of their jobs—which they describe as far more mundane, tedious and boring. Some claim these modern TV shows have changed individuals' expectations of forensic science, sometimes unrealistically—an influence termed the "CSI effect". Further, research has suggested that public misperceptions about criminal forensics can create, in the mind of a juror, unrealistic expectations of forensic evidence—which they expect to see before convicting—implicitly biasing the juror towards the defendant. Citing the "CSI effect", at least one researcher has suggested screening jurors for their level of influence from such TV programs. Further, research has shown that newspaper media has been found to shape readers general knowledge and perceptions of science and technology in a rather positive way. It could lead to support of it due to the interest readers may obtain and seek further knowledge on the topic.
Sources: en.wikipedia.org
== Renal Impairment == Dose adjustment is necessary based on the degree of renal function: Mild Renal Impairment (eGFR ≥ 60 mL/min/1.73 m²): No dose adjustment required. Moderate Renal Impairment (eGFR 30–59 mL/min/1.73 m²): Reduce dose to 50 mg once weekly. Severe Renal Impairment or ESRD (eGFR < 30 mL/min/1.73 m² or on dialysis): Reduce dose to 25 mg once weekly, with close monitoring.
== Bodily location == In mammals, gluconeogenesis has been believed to be restricted to the liver, the kidney, the intestine, and muscle, but recent evidence indicates gluconeogenesis occurring in astrocytes of the brain. These organs use somewhat different gluconeogenic precursors. The liver preferentially uses lactate, glycerol, and glucogenic amino acids (especially alanine) while the kidney preferentially uses lactate, glutamine and glycerol. Lactate from the Cori cycle is quantitatively the largest source of substrate for gluconeogenesis, especially for the kidney. The liver uses both glycogenolysis and gluconeogenesis to produce glucose, whereas the kidney only uses gluconeogenesis. After a meal, the liver shifts to glycogen synthesis, whereas the kidney increases gluconeogenesis. The intestine uses mostly glutamine and glycerol. Propionate is the principal substrate for gluconeogenesis in the ruminant liver, and the ruminant liver may make increased use of gluconeogenic amino acids (e.g., alanine) when glucose demand is increased. The capacity of liver cells to use lactate for gluconeogenesis declines from the preruminant stage to the ruminant stage in calves and lambs. In sheep kidney tissue, very high rates of gluconeogenesis from propionate have been observed. In all species, the formation of oxaloacetate from pyruvate and TCA cycle intermediates is restricted to the mitochondrion, and the enzymes that convert phosphoenolpyruvic acid (PEP) to glucose-6-phosphate are found in the cytosol.
Potash is primarily a mixture of potassium salts because plants have little or no sodium content, and the rest of a plant's major mineral content consists of calcium salts of relatively low solubility in water. While potash has been used since ancient times, its composition was not understood. Georg Ernst Stahl obtained experimental evidence that led him to suggest the fundamental difference of sodium and potassium salts in 1702, and Henri Louis Duhamel du Monceau was able to prove this difference in 1736. The exact chemical composition of potassium and sodium compounds, and the status as chemical element of potassium and sodium, was not known then, and thus Antoine Lavoisier did not include the alkali in his list of chemical elements in 1789. For a long time the only significant applications for potash were the production of glass, bleach, soap and gunpowder as potassium nitrate. Potassium soaps from animal fats and vegetable oils were especially prized because they tend to be more water-soluble and of softer texture, and are therefore known as soft soaps. The discovery by Justus Liebig in 1840 that potassium is a necessary element for plants and that most types of soil lack potassium caused a steep rise in demand for potassium salts. Wood-ash from fir trees was initially used as a potassium salt source for fertilizer, but, with the discovery in 1868 of mineral deposits containing potassium chloride near Staßfurt, Germany, the production of potassium-containing fertilizers began at an industrial scale.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.